Premium
Helicobacter pylori eradication with proton pump inhibitor‐based triple therapies and re‐treatment with ranitidine bismuth citrate‐based triple therapy
Author(s) -
Vittorio Rinaldi,
Angelo Zullo,
Vincenzo De Francesco,
Cesare Hassan,
Simon Winn,
V. Stoppino,
D. Faleo,
Adolfo Francesco Attili
Publication year - 1999
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1999.00462.x
Subject(s) - medicine , omeprazole , helicobacter pylori , gastroenterology , clarithromycin , rapid urease test , lansoprazole , ranitidine hydrochloride , proton pump inhibitor , pantoprazole , amoxicillin , tinidazole , ranitidine , gastritis , antibiotics , metronidazole , microbiology and biotechnology , biology
Background: It has been suggested that short‐term triple therapy comprising a proton pump inhibitor, plus clarithromycin and amoxycillin be used as first choice in treating H. pylori infection, while eradication failure patients should be further treated with a quadruple therapy. Nevertheless, conflicting results have been reported using these treatment regimens in different countries. Methods: A total of 278 patients with H. pylori infection were randomised to receive one‐week triple therapy, comprising clarithromycin 500 mg b.d., amoxycillin 1 g b.d., and either omeprazole 20 mg b.d. (OAC; 90 patients), or pantoprazole 40 mg b.d. (PAC; 95 patients), or lansoprazole 30 mg b.d. (LAC; 93 patients). H. pylori infection at entry, and eradication 4–6 weeks after therapy had ended, were assessed by rapid urease test and histology on biopsies from the antrum and the corpus. When eradication did not occur, patients were given a 2‐week treatment comprising ranitidine bismuth citrate 400 mg b.d., tetracycline 500 mg t.d.s. and tinidazole 500 mg b.d. (RBTT). Eradication in these patients was assessed 4–6 weeks after conclusion of treatment by a further endoscopy. Results: Six patients were lost to the follow‐up. At the end of the first course of treatment, the overall H. pylori eradication rate was 78% (95% CI: 73–83) and 79% (95% CI: 75–84) at ‘intention‐to‐treat’ (ITT) and ‘per protocol’ (PP) analysis, respectively, without any statistically significant difference between treatment regimens, although a trend for better results with the omeprazole combination was observed. Moreover, H. pylori eradication was achieved in 82% (95% CI: 75–97) (ITT) and 86% (95% CI: 69–94) (PP) of 38 patients re‐treated with RBTT regimen. Conclusions: Our data found that this short‐term triple therapy is not a satisfactory treatment (< 80% eradication rate) for H. pylori infection. The 2‐week triple therapy used as re‐treatment in eradication failure patients yielded more promising results.